Please use this identifier to cite or link to this item:
https://doi.org/10.1038/onc.2017.334
DC Field | Value | |
---|---|---|
dc.title | Oncogenic RAS-induced CK1? drives nuclear FOXO proteolysis | |
dc.contributor.author | Zhang, F | |
dc.contributor.author | Virshup, D.M | |
dc.contributor.author | Cheong, J.K | |
dc.date.accessioned | 2020-09-09T04:12:12Z | |
dc.date.available | 2020-09-09T04:12:12Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Zhang, F, Virshup, D.M, Cheong, J.K (2018). Oncogenic RAS-induced CK1? drives nuclear FOXO proteolysis. Oncogene 37 (3) : 363-376. ScholarBank@NUS Repository. https://doi.org/10.1038/onc.2017.334 | |
dc.identifier.issn | 0950-9232 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/175130 | |
dc.description.abstract | Evasion of forkhead box O (FOXO) family of longevity-related transcription factors-mediated growth suppression is necessary to promote cancer development. Since somatic alterations or mutations and transcriptional dysregulation of the FOXO genes are infrequent in human cancers, it remains unclear how these tumour suppressors are eliminated from cancer cells. The protein stability of FOXO3A is regulated by Casein Kinase 1 alpha (CK1?) in an oncogenic RAS-specific manner, but whether this mode of regulation extends to related FOXO family members is unknown. Here we report that CK1? similarly destabilizes FOXO4 in RAS-mutant cells by phosphorylation at serines 265/268. The CK1?-dependent phosphoregulation of FOXO4 is primed, in part, by the PI3K/AKT effector axis of oncogenic RAS signalling. In addition, mutant RAS coordinately elevates proteasome subunit expression and proteolytic activity to eradicate nuclear FOXO4 proteins from RAS-mutant cancer cells. Importantly, dual inhibition of CK1? and the proteasome synergistically inhibited the growth of multiple RAS-mutant human cancer cell lines of diverse tissue origin by blockade of nuclear FOXO4 degradation and induction of caspase-dependent apoptosis. Our findings challenge the current paradigm that nuclear export regulates the proteolysis of FOXO3A/4 tumour suppressors in the context of cancer and illustrates how oncogenic RAS-mediated degradation of FOXOs, via post-translational mechanisms, blocks these important tumour suppressors. © 2018 The Author(s). | |
dc.publisher | Nature Publishing Group | |
dc.source | Unpaywall 20200831 | |
dc.subject | casein kinase Ialpha | |
dc.subject | caspase | |
dc.subject | nuclear protein | |
dc.subject | phosphatidylinositol 3 kinase | |
dc.subject | proteasome | |
dc.subject | protein FOXO4 | |
dc.subject | protein kinase B | |
dc.subject | Ras protein | |
dc.subject | serine | |
dc.subject | transcription factor FKHRL1 | |
dc.subject | transcription factor FOXO | |
dc.subject | tumor suppressor protein | |
dc.subject | unclassified drug | |
dc.subject | 4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide | |
dc.subject | benzamide derivative | |
dc.subject | casein kinase Ialpha | |
dc.subject | FOXO3 protein, human | |
dc.subject | FOXO4 protein, human | |
dc.subject | imidazole derivative | |
dc.subject | KRAS protein, human | |
dc.subject | proteasome | |
dc.subject | proteasome inhibitor | |
dc.subject | protein p21 | |
dc.subject | serine | |
dc.subject | small interfering RNA | |
dc.subject | transcription factor | |
dc.subject | transcription factor FKHRL1 | |
dc.subject | apoptosis | |
dc.subject | Article | |
dc.subject | cancer cell line | |
dc.subject | cancer growth | |
dc.subject | cell mutant | |
dc.subject | colon cancer | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | nuclear export | |
dc.subject | priority journal | |
dc.subject | protein degradation | |
dc.subject | protein expression | |
dc.subject | protein induction | |
dc.subject | protein phosphorylation | |
dc.subject | protein processing | |
dc.subject | regulatory mechanism | |
dc.subject | signal transduction | |
dc.subject | antagonists and inhibitors | |
dc.subject | cell cycle | |
dc.subject | cell nucleus | |
dc.subject | drug effect | |
dc.subject | genetics | |
dc.subject | metabolism | |
dc.subject | mutation | |
dc.subject | neoplasm | |
dc.subject | pathology | |
dc.subject | phosphorylation | |
dc.subject | protein degradation | |
dc.subject | tumor cell line | |
dc.subject | Apoptosis | |
dc.subject | Benzamides | |
dc.subject | Casein Kinase Ialpha | |
dc.subject | Cell Cycle | |
dc.subject | Cell Line, Tumor | |
dc.subject | Cell Nucleus | |
dc.subject | Forkhead Box Protein O3 | |
dc.subject | Humans | |
dc.subject | Imidazoles | |
dc.subject | Mutation | |
dc.subject | Neoplasms | |
dc.subject | Phosphorylation | |
dc.subject | Proteasome Endopeptidase Complex | |
dc.subject | Proteasome Inhibitors | |
dc.subject | Protein Processing, Post-Translational | |
dc.subject | Proteolysis | |
dc.subject | Proto-Oncogene Proteins p21(ras) | |
dc.subject | RNA, Small Interfering | |
dc.subject | Serine | |
dc.subject | Signal Transduction | |
dc.subject | Transcription Factors | |
dc.type | Article | |
dc.contributor.department | DUKE-NUS MEDICAL SCHOOL | |
dc.description.doi | 10.1038/onc.2017.334 | |
dc.description.sourcetitle | Oncogene | |
dc.description.volume | 37 | |
dc.description.issue | 3 | |
dc.description.page | 363-376 | |
dc.published.state | Published | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1038_onc_2017_334.pdf | 7.94 MB | Adobe PDF | OPEN | None | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.